And I didn't need a whole year to feel better
Outcomes Primary and Secondary Outcome Patients in the semaglutide study arm experienced a significantly lower rate of the primary outcome (cardiovascular composite end-point) (6.5% vs 8.0%, HR 0.80 (95% CI 0.72-0.90) No significant difference in rates of cardiac death (HR 0.85, 95% CI 0.71-1.01) however significantly lower rates of heart failure (HR 0.82, 95% CI 0.71-0.96) and all-cause mortality (HR 0.81, 95% CI 0.71-0.93) Adverse Events Rates and types of adverse events were fairly similar between control and intervention groups Permanent premature discontinuation of semaglutide or placebo occurred in 2351 patients (26.7%) in the semaglutide group and 2078 (23.6%) in the placebo group In obese and overweight patients with cardiovascular comorbidities but without diabetes, treatment with weekly semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months
Bachmeyer achieve success in both his personal and professional life
Further research into its role in fatty liver disease (NASH/MASLD) and polycystic ovary syndrome (PCOS) is also ongoing
Clinical Update 5/15/2025 Sunscreens & Rosacea Find out which sunscreens and foundations with sunscreen do not contain ingredients known to trigger rosacea
From a research design perspective, the choice between compounds depends on the specific metabolic pathway under investigation: Retatrutide is appropriate for research models where maximum energy expenditure, lipolysis, and hepatic fat reduction are primary endpoints, and where the glucagon receptor pathway is specifically relevant to the study design
